cholangiocarcinoma


Also found in: Dictionary, Acronyms, Wikipedia.

cholangiocarcinoma

 [ko-lan″je-o-kahr″sĭ-no´mah]
1. an adenocarcinoma arising from the epithelium of the intrahepatic bile ducts, composed of eosinophilic cuboidal or columnar epithelial cells, with abundant fibrous stroma; mucus may be secreted but not bile.

chol·an·gi·o·car·ci·no·ma

(kō-lan'jē-ō-kar'si-nō'mă),
An adenocarcinoma, primarily in intrahepatic bile ducts, composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant fibrous stroma; cirrhosis is usually absent.

cholangiocarcinoma

/cho·lan·gi·o·car·ci·no·ma/ (ko-lan″je-o-kahr″sĭ-no´mah)
1. an adenocarcinoma arising from the epithelium of the intrahepatic bile ducts and composed of epithelial cells in tubules or acini with fibrous stroma.

cholangiocarcinoma

[kōlan′jē·ōkär′sinō′mə]
a cancer of the biliary epithelium. Risk factors include ulcerative colitis and infestation of liver flukes. Diagnosis is based on histological evaluation, and the prognosis is poor.

cholangiocarcinoma

A rare (5/105/year) cancer of intrahepatic bile ducts, seen > age 60.
 
Aetiology
Anabolic steroids, liver flukes (Clonorchis sinensis), ulcerative colitis, cholecystitis, cholelithiasis, primary sclerosing cholangitis, malformations, cirrhosis.

Clinical findings
Obstruction, jaundice, abdominal pain, weight loss.

Location
Hilar, 50–60%; intrahepatic, 10%; extrahepatic 20–30%.

Prognosis
53% 1-year survival; 4% 5-year survival.

cholangiocarcinoma

Bile duct cancer, cancer of bile ducts A rare–5/100,000/yr cancer of intrahepatic bile ducts seen > age 60 Etiology Anabolic steroids, Thorotrast,.Clonorchis sinensis, possibly ulcerative cholitis, cholecystitis; not associated with alcohol abuse Clinical Jaundice—71%, abdominal pain-49%, weight loss—44% Prognosis 53% 1-yr survival, 9% 3-yr, 4% 5-yr. Cf Hepatocellular carcinoma.

chol·an·gi·o·car·ci·no·ma

(kō-lan'jē-ō-kahr-si-nō'mă)
An adenocarcinoma, primarily in intrahepatic bile ducts, composed of ducts lined by cuboidal or columnar cells that do not contain bile, with abundant fibrous stroma.

cholangiocarcinoma

Cancer of the bile ducts.

cholangiocarcinoma

see cholangiocellular carcinoma.
References in periodicals archive ?
Metastatic adenocarcinoma to the liver from the pancreas, colon, upper gastrointestinal tract, lung, breast, and other sites can closely mimic cholangiocarcinoma histologically.
PTC is performed primarily in patients in whom ERCP has failed, or when altered anatomy precludes access to the ampulla, and for biliary drainage and stenting in patients with irresectable hilar cholangiocarcinoma.
The most common diagnoses made were adenocarcinoma of the pancreas, pancreatitis, renal cell carcinoma and cholangiocarcinoma.
Key Words: pancreatic cancer, cholangiocarcinoma, endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, magnetic resonance cholangiopancreatography, transhepatic cholangiography
felineus infection and cholangiocarcinoma was studied in the Tyumen region, Russia.
3) In this article, we describe a unique case of cholangiocarcinoma metastasis to a cervical lymph node.
We retrospectively reviewed all patients with cholangiocarcinoma or gallbladder cancer treated at Baylor University Medical Center (BUMC) and determined how often the pancreaticobiliary junction was visualized and how often an abnormal junction was identified.
Announces First TargetCancer Think Tank and Cholangiocarcinoma Cell Line Bank
Physicians in Europe have used CHEMOSAT in both commercial and clinical settings to treat patients for a wide variety of cancers in the liver, including ocular melanoma liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and liver metastases from colorectal cancer, breast cancer and others.
Cholangiocarcinoma (CCC, or bile duct cancer) represents the second most frequent primary liver tumor and has emerged as a health problem with sharply increasing incidence rates, in particular of intrahepatic CCC (ICC).
NHS revision of Clinical Policy Commissioning Statement on SIRT will allow patients in England with metastatic colorectal cancer (mCRC) and intrahepatic cholangiocarcinoma (ICC) who may benefit from SIR-Spheres microspheres to get treatment in specialist NHS centres
The Alan Morement Memorial Fund (AMMF) is the UK's only dedicated cholangiocarcinoma (CC) charity and was put forward by paralegal Marcella Smith, who lost her husband to the disease.